Lutetium Lu 177 dotatate

Generic Name
Lutetium Lu 177 dotatate
Brand Names
Lutathera
Drug Type
Small Molecule
Chemical Formula
C65H87LuN14O19S2
CAS Number
437608-50-9
Unique Ingredient Identifier
AE221IM3BB
Background

A 177Lu-labeled somatostatin analog peptide, Lutetium Lu 177 dotatate belongs to an emerging form of treatments called Peptide Receptor Radionuclide Therapy (PRRT), which involves targeting tumours with molecules carrying radioactive particles that bind to specific receptors expressed by the tumour. Lutetium Lu 177 dotatate may also be referred to as 177Lu-D...

Indication

Indicated for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors in adults .

Associated Conditions
Gastroenteropancreatic Neuroendocrine Tumors
Associated Therapies
-

Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Pancreatic Neuroendocrine Tumors

First Posted Date
2021-02-11
Last Posted Date
2024-12-20
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
29
Registration Number
NCT04750954
Locations
🇺🇸

University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida, United States

🇺🇸

Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

🇺🇸

Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States

and more 2 locations

Lutathera in People With Gastroenteropancreatic (GEP), Bronchial or Unknown Primary Neuroendocrine Tumors That Have Spread to the Liver

First Posted Date
2020-09-10
Last Posted Date
2024-05-02
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
10
Registration Number
NCT04544098
Locations
🇺🇸

Memorial Sloan Kettering Cancer Center, New York, New York, United States

177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast Cancer

First Posted Date
2020-08-27
Last Posted Date
2024-12-20
Lead Sponsor
OHSU Knight Cancer Institute
Target Recruit Count
10
Registration Number
NCT04529044
Locations
🇺🇸

OHSU Knight Cancer Institute, Portland, Oregon, United States

A Clinical Study to Assess the Combination of Two Drugs (177Lu-DOTATATE and Nivolumab) in Neuroendocrine Tumours

First Posted Date
2020-08-25
Last Posted Date
2022-08-02
Lead Sponsor
Fundación de investigación HM
Target Recruit Count
30
Registration Number
NCT04525638
Locations
🇪🇸

Complexo Hospitalario Universitario de Santiago, Santiago De Compostela, Galicia, Spain

🇪🇸

Hospital Unviersitario Ramón y Cajal, Madrid, Spain

🇪🇸

Hospital Universitario 12 de Octubre, Madrid, Spain

and more 2 locations

Neoadjuvant PRRT With 177Lu-DOTATATE Followed by Surgery for Resectable PanNET

Phase 2
Completed
Conditions
Interventions
First Posted Date
2020-05-13
Last Posted Date
2023-06-27
Lead Sponsor
IRCCS San Raffaele
Target Recruit Count
31
Registration Number
NCT04385992
Locations
🇮🇹

Ospedale San Raffaele, Milano, Italy

Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors

First Posted Date
2020-01-21
Last Posted Date
2024-12-04
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
29
Registration Number
NCT04234568
Locations
🇺🇸

Northwestern University, Chicago, Illinois, United States

🇺🇸

Mayo Clinic in Rochester, Rochester, Minnesota, United States

🇺🇸

Mayo Clinic Hospital in Arizona, Phoenix, Arizona, United States

and more 8 locations

Dosimetry Guided PRRT With 177Lu-DOTATATE in Children and Adolescents

First Posted Date
2019-04-22
Last Posted Date
2021-06-08
Lead Sponsor
Sue O'Dorisio
Registration Number
NCT03923257
Locations
🇺🇸

University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States

© Copyright 2024. All Rights Reserved by MedPath